Last reviewed · How we verify
Dexlansoprazole MR
Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells.
Dexlansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in parietal cells. Used for Gastroesophageal reflux disease (GERD), Healing of erosive esophagitis, Maintenance of healed erosive esophagitis.
At a glance
| Generic name | Dexlansoprazole MR |
|---|---|
| Also known as | TAK-390MR, Kapidex, Dexilant |
| Sponsor | Takeda |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Dexlansoprazole is the active R-enantiomer of lansoprazole, a proton pump inhibitor (PPI). It binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, reducing both basal and stimulated gastric acid production. The modified-release (MR) formulation provides dual-peak plasma concentrations to extend acid suppression throughout the day.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Healing of erosive esophagitis
- Maintenance of healed erosive esophagitis
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Upper respiratory tract infection
Key clinical trials
- Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy (NA)
- A Study of Dexlansoprazole Modified Release (MR) in Gastroesophageal Reflux Disease (GERD) Participants in the Russian Federation
- Dexlansoprazole MR-Based Concomitant Quadruple Therapy (NA)
- Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn (PHASE3)
- Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection (PHASE4)
- Dexlansoprazole MR in Nonerosive Reflux Disease (NA)
- Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis (PHASE3)
- Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |